Skip to main content Skip to navigation

Participant Information

Welcome to the METEOR2 Study!

The METEOR2 is a study for people who have had some meniscus (cushioning cartilage) removed from their knee, don’t have diagnosed arthritis of the knee but still have pain more than 6 months afterwards.

The meniscus is cushioning cartilage in the knee which protects the joint from wear. Tears of the meniscus are common and can occur following traumatic injuries (caused during a significant, memorable injury to the knee, including sporting injuries) or from degenerative tears, which occur over time.

Tears of the meniscus are often treated by an operation called a meniscectomy. This involves the removal of cartilage in the knee. After this operation, most people's pain and symptoms improve over time. For some people, the pain and symptoms get worse.


METEOR2 is looking for people who have:

  1. Have been treated by having meniscus removed at least 6 months previously.
  2. Are still experiencing pain or other symptoms.

To be eligible for the study, patients cannot have arthritis of the knee.

Two possible treatment options for these types of patients are:

Personalised Knee Therapy

Meniscal Transplant

Personalised knee therapy (physiotherapy, sometimes bracing, advice on work or activities and how to improve pain; may also be known as optimised rehabilitation).

An operation to insert a replacement meniscus taken from someone who has died, this is known as a 'meniscal transplant'.

We do not know whether this problem is best treated with personalised knee therapy or surgery to replace the meniscus. Both treatments could improve pain and restrictions.

METEOR2 aims to find out which of these treatments is best. Participants will be randomly allocated to either treatment and we will follow up on their recovery progress. We plan to recruit 144 participants from hospitals across the UK and internationally, including Australia, Canada and Belgium.

If you would like to find out more about the study, you can read our patient information sheetLink opens in a new window.

  • For UK based patients:

If you think you may be eligible for the study and would like to take part, please contact your GP and request that you are referred to one of our participating sites:

  • Instructions for Australian patients:

Co-Investigator: Manuela Ferreira

Trial Coordinators: Clare Goodson, Michael Knox, Eric Weiss




    Contact us

    Chief Investigator: Andrew Metcalfe & Mr Timothy Spalding

    UK Study Team Email:

    Australia Study Team Email: opens in a new window

    Sites open to recruitment:


    • Musgrave Park Hospital - Belfast
    • Southmead Hospital - Bristol
    • Addenbrooke's Hospital - Cambridge
    • Rotherham General Hospital
    • University Hospital Coventry & Warwickshire
    • University Hospital College London
    • Royal National Orthopaedic
    • Lanarkshire University Hospitals
    • Nuffield Orthopaedic Centre - Oxford
    • Gloucester Royal Hospital
    • Nuffield Orthopaedic Centre, Oxford
    • Wrightington Hospital
    • Royal Devon & Exeter
    • The Royal Orthopaedic - Birmingham
    • Queen Elizabeth University Hospital - Glasgow


    • Royal North Shore Hospital
    • North Shore Private Hospital
    • Brisbane Private Hospital